Yuanma Therapeutics

Yuanma Therapeutics is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of precision oncology treatments. The company utilizes its proprietary AI-driven platform, DeepCode, to identify novel therapeutic targets and biomarkers, with a primary focus on the concept of synthetic lethality. Its pipeline features several small molecule inhibitors, including YM-101, a potent USP1 inhibitor currently undergoing Phase 1 clinical trials for advanced solid tumors. Other programs in development include inhibitors targeting WRN and Polθ, aimed at treating cancers with specific genetic vulnerabilities like microsatellite instability or homologous recombination deficiency. By integrating multi-omics data and advanced computational tools, Yuanma Therapeutics seeks to deliver highly targeted therapies to patients with unmet medical needs. The company is backed by prominent investors such as GL Ventures and IDG Capital.